China Biologic Products Holdings Inc Quick Ratio (CBPO) starting from the fourth quarter 2019 to fourth quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
China Biologic Products Holdings Inc   (NASDAQ: CBPO)

China Biologic Products Holdings Inc 's Quick Ratio

CBPO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


China Biologic Products Holdings Inc 's Cash & cash equivalent grew by 307.68 % in the Q4 2019 sequentially, faster than Current Liabilities, this led to improvement in China Biologic Products Holdings Inc 's Quick Ratio to 3.99, Quick Ratio remained below China Biologic Products Holdings Inc average.

Within Biotechnology & Pharmaceuticals industry 78 other companies have achieved higher Quick Ratio than China Biologic Products Holdings Inc in fourth quarter 2019. While Quick Ratio total ranking has improved so far during the Q4 2019 to 1204, from total ranking in the third quarter 2019 at 1967.

Explain Quick Ratio?
How much Cash & cash equivalents CBPO´s has?
What are CBPO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CBPO Quick Ratio (Dec 31 2019)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2018)
Q4
Y / Y Current Liabilities Change 259.7 % -2.48 % -2.48 % -2.48 % -67.86 %
Y / Y Cash & cash equivalent Change -30.76 % -83.02 % -83.02 % -83.02 % 151.99 %
Quick Ratio MRQ 3.99 1.36 1.36 1.36 20.72
CBPO's Total Ranking # 1204 # 1967 # 2050 # 1995 # 373
Seq. Current Liabilities Change 38.56 % 0 % 0 % 159.6 % -62.44 %
Seq. Cash & cash equivalent Change 307.68 % 0 % 0 % -83.02 % 0 %



Quick Ratio fourth quarter 2019 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 79
Healthcare Sector # 407
Overall Market # 1165


Quick Ratio Statistics
High Average Low
20.72 4.78 0.79
(Dec 31 2018)   (Mar 31 2014)




Financial Statements
China Biologic Products Holdings Inc 's Current Liabilities $ 165 Millions Visit CBPO's Balance sheet
China Biologic Products Holdings Inc 's Cash & cash equivalent $ 659 Millions Visit CBPO's Balance sheet
Source of CBPO's Sales Visit CBPO's Sales by Geography


Cumulative China Biologic Products Holdings Inc 's Quick Ratio

CBPO's Quick Ratio for the trailling 12 Months

CBPO Quick Ratio

 (Dec 31 2019)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2018)
12 Months
Y / Y Current Liabilities TTM Growth 26.69 % -20.81 % -16.15 % 0.92 % 29.4 %
Y / Y Cash & cash equivalent TTM Growth -69.95 % -55.56 % -11.75 % 65.99 % 250.61 %
Quick Ratio TTM 2.19 3.56 5.48 7.36 9.22
Total Ranking TTM # 1326 # 4389 # 4246 # 4576 # 4750
Seq. Current Liabilities TTM Growth 29.55 % -0.75 % -0.74 % -0.74 % -19.02 %
Seq. Cash & cash equivalent TTM Growth -20.38 % -35.48 % -26.19 % -20.75 % 17.76 %

Quick ratio ranking by company, industry and sector >> Back to CBPO Financial Strength Comparisons >> Go to Compare CBPO Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q4 2019 to $165.31 millions, cumulative Quick Ratio decreased to 2.19 below the China Biologic Products Holdings Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 94 other companies have achieved higher Quick Ratio than China Biologic Products Holdings Inc . While Quick Ratio overall ranking has improved so far to 1326, from total ranking during the twelve months ending third quarter 2019 at 4389.

Explain Quick Ratio?
How much Cash & cash equivalents CBPO´s has?
What are CBPO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 95
Healthcare Sector # 562
Within the Market # 1326


trailing twelve months Quick Ratio Statistics
High Average Low
7.78 2.49 1.25
(Dec 31 2018)   (March 31, 2015)




Companies with similar Quick Ratio in the quarter ending Dec 31 2019, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2019 MRQ Cash & cash equivalentDec 31 2019 MRQ Current Liabilities
Repligen Corp  10.97 $ 528.392  Millions$ 48.178  Millions
Immunovant Inc   10.63 $ 123.530  Millions$ 11.623  Millions
Inmune Bio Inc   9.99 $ 6.996  Millions$ 0.700  Millions
Aligos Therapeutics Inc   9.80 $ 117.663  Millions$ 12.003  Millions
Voyager Therapeutics Inc   9.78 $ 281.533  Millions$ 28.779  Millions
Iovance Biotherapeutics inc   9.65 $ 307.081  Millions$ 31.832  Millions
Entera Bio Ltd   9.48 $ 15.185  Millions$ 1.601  Millions
Autolus Therapeutics Plc  9.21 $ 210.643  Millions$ 22.864  Millions
Regenxbio Inc   8.80 $ 296.210  Millions$ 33.676  Millions
Compugen Ltd  8.59 $ 43.879  Millions$ 5.108  Millions
Denali Therapeutics Inc   8.20 $ 415.356  Millions$ 50.643  Millions
Ladrx Corporation  7.87 $ 16.130  Millions$ 2.050  Millions
Editas Medicine Inc   7.62 $ 457.140  Millions$ 59.963  Millions
Mosaic Immunoengineering Inc   7.61 $ 1.736  Millions$ 0.228  Millions
Adverum Biotechnologies Inc   7.23 $ 166.035  Millions$ 22.966  Millions
Atara Biotherapeutics Inc   7.05 $ 259.109  Millions$ 36.743  Millions
Forma Therapeutics Holdings Inc.  6.96 $ 173.180  Millions$ 24.868  Millions
Compass Therapeutics Inc   6.75 $ 25.303  Millions$ 3.751  Millions
Precision Biosciences Inc  6.72 $ 180.886  Millions$ 26.932  Millions
Genocea Biosciences Inc   6.39 $ 40.127  Millions$ 6.281  Millions
Revolution Medicines Inc   6.11 $ 122.758  Millions$ 20.104  Millions
Vir Biotechnology Inc   6.02 $ 389.617  Millions$ 64.721  Millions
Exelixis Inc   5.97 $ 852.243  Millions$ 142.746  Millions
Lineage Cell Therapeutics Inc   5.83 $ 30.716  Millions$ 5.271  Millions
Gritstone Bio Inc   5.78 $ 127.776  Millions$ 22.110  Millions
Alector Inc   5.70 $ 353.073  Millions$ 61.970  Millions
Orchard Therapeutics Plc  5.68 $ 324.990  Millions$ 57.177  Millions
Surface Oncology Inc   5.46 $ 105.161  Millions$ 19.274  Millions
Cellectis S a   5.44 $ 340.522  Millions$ 62.604  Millions
Sangamo Therapeutics Inc   5.34 $ 362.474  Millions$ 67.897  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.